Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer

Prostate Cancer and Prostatic Diseases volume 8, pages 179–183 (2005)Cite this article

Abstract

Objective:

To determine whether the duration of the off-treatment interval in patients being treated with intermittent androgen deprivation therapy can be predicted by the length of the CAG trinucleotide repeat polymorphism in the androgen receptor.

Methods:

This is a companion study to a prospective randomized trial, NCIC CTG PR-7, comparing intermittent to continuous androgen deprivation therapy in men with PSA progression after radiation therapy. The duration of the first off-treatment interval was established for 76 participants randomized to the intermittent therapy arm of the trial. Androgen receptor CAG repeat polymorphism lengths were determined for these 76 participants. Statistical analysis was completed to determine a relationship between CAG repeat length and the duration of the off-treatment interval.

Results:

A significant correlation was not established (P=0.424) between androgen receptor CAG repeat length and the duration of the first off-treatment interval. Categorical analysis of CAG repeat lengths using 18 and 22 as cutoff points did not find any significant difference in the mean duration of the off-treatment interval between categories (P=0.672 and 0.774, respectively).

Conclusion:

No relationship was established between the duration of the first off-treatment interval and the CAG repeat length.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Klotz LH et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 2546–2560.

    Article  CAS  Google Scholar 

  2. Pether M, Goldenberg SL . Intermittent androgen suppression. Br J Urol Int 2004; 93: 258–261.

    Article  CAS  Google Scholar 

  3. Edwards A et al. Genetic variation at five trimeric and tetrameric tandem repeat risk. Cancer Res 1997; 57: 1194–1198.

    Google Scholar 

  4. Chamberlain N, Driver E, Meisfeld R . The length and location of the CAG trinucleotide repeats in the androgen receptor of N terminal domain affect on transactivation function. Nuclec Acid Res 1994; 22: 3181–3186.

    Article  CAS  Google Scholar 

  5. Nelson KA, Witte JS . Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol 2002; 155: 883–890.

    Article  Google Scholar 

  6. Hakimi J, Rondinelli R, Schoenberg M, Banack E . Androgen receptor gene structure and function in prostate cancer. World J Urol 1996; 14: 329–337.

    Article  CAS  Google Scholar 

  7. Edwards KJ et al. The CAG trinucleotide repeat length in the androgen receptor does not predict the early onset of prostate cancer. Br J Urol Int 2002; 90: 573–578.

    Article  Google Scholar 

  8. Irvine R, Yu M, Ross R, Coetzee G . The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995; 55: 1937–1940.

    CAS  PubMed  Google Scholar 

  9. Giovanucci E et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997; 94: 3320–3323.

    Article  Google Scholar 

  10. Bratt O et al. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 1999; 81: 672–676.

    Article  CAS  Google Scholar 

  11. Hardy DO et al. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 1996; 81: 4400–4405.

    CAS  PubMed  Google Scholar 

  12. Ingles SA et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997; 89: 166–170.

    Article  CAS  Google Scholar 

  13. Hakimi JM et al. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 1997; 3: 1599–1608.

    CAS  PubMed  Google Scholar 

  14. Stanford JL et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997; 57: 1194–1198.

    CAS  PubMed  Google Scholar 

  15. Correa-Cerro L et al. (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French–German population. Eur J Hum Genet 1999; 7: 357–362.

    Article  CAS  Google Scholar 

  16. Edwards SM et al. Androgen receptor polymorphisms: association with prostate cancer risk, relapse, and overall survival. Int J Cancer 1999; 84: 458–465.

    Article  CAS  Google Scholar 

  17. Nam R et al. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol 2000; 164: 567–572.

    Article  CAS  Google Scholar 

  18. Suzuki H et al. CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: potential predictor of prognosis after endocrine therapy. Prostate 2002; 51: 219–224.

    Article  CAS  Google Scholar 

  19. Pinker-Shaeffer C et al. Molecular and cellular changes associated with the acquisition of metastatic ability by prostate cancer cells. Prostate 1994; 25: 249–265.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Canada

    L Klotz, A Correia & W Zhang

Authors
  1. L Klotz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Correia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Klotz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klotz, L., Correia, A. & Zhang, W. The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer. Prostate Cancer Prostatic Dis 8, 179–183 (2005). https://doi.org/10.1038/sj.pcan.4500792

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500792

Keywords

This article is cited by

Search

Advanced search

Quick links